Chemotherapy-Free combo aims to boost remission in younger AML patients
NCT ID NCT03573024
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether a combination of two drugs, venetoclax and azacitidine, can effectively treat adults aged 18 to 59 who have been newly diagnosed with acute myeloid leukemia (AML) and have not yet received any treatment. Participants take both drugs in cycles, with venetoclax taken by mouth and azacitidine given as a shot or IV. The study measures how many patients achieve complete remission or other positive responses, and how long those responses last.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
venetoclax and azacitidine
What this could lead to
If successful, this drug combination could offer a new, chemotherapy-free treatment option for younger adults with acute myeloid leukemia, potentially improving remission rates.
What could go wrong
This is a phase 2 trial with only 36 participants, so results are preliminary. The combination may cause side effects like low blood counts or infections, and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Universtiy of Colorado Hospital
Aurora, Colorado, 80045, United States